Chronic Treatment of Silymarin Improves Hyperalgesia and Motor Nerve Conduction Velocity in Diabetic Neuropathic Rat

被引：26
作者：
Baluchnejadmojarad, Tourandokht [1 ]
Roghani, Mehrdad [2 ,3 ]
Khastehkhodaie, Zeynab [1 ]
机构：
[1] Iran Univ Med Sci, Dept Physiol, Sch Med, Tehran, Iran
[2] Shahed Univ Tehran, Dept Physiol, Tehran, Iran
[3] Shahed Univ Tehran, Med Plant Res Ctr, Sch Med, Tehran, Iran
来源：
PHYTOTHERAPY RESEARCH | 2010年 / 24卷 / 08期
关键词：
silymarin; diabetic neuropathy; hyperalgesia; ALDOSE REDUCTASE INHIBITOR; ALPHA-LIPOIC ACID; OXIDATIVE STRESS; FORMALIN TEST; MECHANICAL HYPERALGESIA; NEUROVASCULAR FUNCTION; THERMAL HYPERALGESIA; LIPID-PEROXIDATION; ANTIOXIDANT STATUS; SILYBUM-MARIANUM;
D O I：
10.1002/ptr.3078
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The effect of chronic silymarin (SM) treatment on hyperalgesia, sciatic motor nerve conduction velocity (MNCV) and oxidative stress in streptozotocin (STZ)-diabetic neuropathic rat was evaluated. Rats were divided into control, diabetic. SM-treated control and diabetic, and sodium salisylate (SS)-treated control and diabetic. SM was administered daily at a dose of 100 mg/kg for two months. Finally, hyperalgesia and sciatic MNCV and oxidative stress markers were assessed. Diabetic rats showed a significant deficit in MNCV and markedly exhibited chemical and thermal hyperalgesia, indicating development of diabetic neuropathy. Antioxidant enzyme superoxide dismutase (SOD) level significantly reduced and malondialdehyde (MDA) level significantly increased in diabetic rats compared to control rats; SM treatment significantly ameliorated the alteration in MNCV, hyperalgesia, MDA level and antioxidant enzyme SOD in diabetic rats. These results clearly suggest the potential effect of SM in prevention and treatment of diabetic neuropathy. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码：1120 / 1125
页数：6
相关论文
共 53 条
[1]  
Anjaneyulu Muragundla, 2004, Indian Journal of Experimental Biology, V42, P766
[2]   Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat [J].
Burnard, SL ;
McMurchie, EJ ;
Leifert, WR ;
Patten, GS ;
Muggli, R ;
Raederstorff, D ;
Head, RJ .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1998, 12 (02) :65-73
[3]   Effects of α-lipoic acid on neurovascular function in diabetic rats:: interaction with essential fatty acids [J].
Cameron, NE ;
Cotter, MA ;
Horrobin, DH ;
Tritschler, HJ .
DIABETOLOGIA, 1998, 41 (04) :390-399
[4]   Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes [J].
Cameron, NE ;
Cotter, MA .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 45 (2-3) :137-146
[5]   Identification of MEK1 as a novel target for the treatment of neuropathic pain [J].
Ciruela, A ;
Dixon, AK ;
Bramwell, S ;
Gonzalez, MI ;
Pinnock, RD ;
Lee, K .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (05) :751-756
[6]  
Coppey Lawrence J, 2002, Int J Exp Diabetes Res, V3, P21, DOI 10.1080/15604280212525
[7]  
COTTER MA, 1995, DIABETOLOGIA, V38, P1285
[8]   Effects of the protein kinase Cβ inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes [J].
Cotter, MA ;
Jack, AM ;
Cameron, NE .
CLINICAL SCIENCE, 2002, 103 (03) :311-321
[9]   STREPTOZOCIN-INDUCED DIABETIC RATS - BEHAVIORAL EVIDENCE FOR A MODEL OF CHRONIC PAIN [J].
COURTEIX, C ;
ESCHALIER, A ;
LAVARENNE, J .
PAIN, 1993, 53 (01) :81-88
[10]   Endothelial dysfunction in diabetes [J].
De Vriese, AS ;
Verbeuren, TJ ;
Van de Voorde, J ;
Lameire, NH ;
Vanhoutte, PM .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (05) :963-974
123456